Juno Therapeutics Inc (JUNO) : Clarius Group scooped up 3,500 additional shares in Juno Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 117,896 shares of Juno Therapeutics Inc which is valued at $3,887,031.Juno Therapeutics Inc makes up approximately 1.83% of Clarius Group’s portfolio.
Other Hedge Funds, Including , Fmr reduced its stake in JUNO by selling 2,520,477 shares or 44.16% in the most recent quarter. The Hedge Fund company now holds 3,186,758 shares of JUNO which is valued at $105,067,411. Juno Therapeutics Inc makes up approx 0.01% of Fmr’s portfolio.Baird Financial Group boosted its stake in JUNO in the latest quarter, The investment management firm added 11,134 additional shares and now holds a total of 23,601 shares of Juno Therapeutics Inc which is valued at $711,334. Juno Therapeutics Inc makes up approx 0.01% of Baird Financial Group’s portfolio.Advisor Group boosted its stake in JUNO in the latest quarter, The investment management firm added 1,296 additional shares and now holds a total of 3,815 shares of Juno Therapeutics Inc which is valued at $108,384.Financial Architects Inc boosted its stake in JUNO in the latest quarter, The investment management firm added 258 additional shares and now holds a total of 558 shares of Juno Therapeutics Inc which is valued at $13,554.
Juno Therapeutics Inc closed down -0.68 points or -2.22% at $29.93 with 10,31,498 shares getting traded on Monday. Post opening the session at $30.69, the shares hit an intraday low of $29.59 and an intraday high of $30.9399 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Juno Therapeutics Inc reported $-0.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Nov 9, 2016. Analyst had a consensus of $-0.58. The company had revenue of $20.80 million for the quarter, compared to analysts expectations of $11.31 million. The company’s revenue was up 1200.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.26 EPS.
Juno Therapeutics Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates JCAR015 JCAR017 and JCAR014 utilize CAR technology to target CD19 a protein expressed on the surface of various B cell leukemias and lymphomas. Juno’s other product candidates include JCAR018: CD22 JCAR023: L1CAM (CD171) JCAR020: MUC-16 / IL-12 ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML myelodysplasic syndrome and chronic myeloid leukemia.